Researchers examined “chilblain-like lesions,” which has been extensively reported in COVID-19 cases, in the blood samples and skin biopsies of 50 patients with COVID-like symptoms at Saint-Louis hospital in France in April 2020.
Researchers found high levels of Type 1 interferon, a protein that activates the body’s immune system to fight viruses, but can also cause damage. The researchers also found high levels of an antibody that can inadvertently attack the body’s own cells.
The study suggested treating the condition with local or systemic anti-inflammatory agents.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.